Related Experiment Videos
A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma
B I Zemann1, A S Moore, W M Rand
1School of Veterinary Medicine, Vienna, Austria.
Journal of Veterinary Internal Medicine
|December 19, 1998
Summary
The VELCAP-L chemotherapy regimen achieved a 69% complete remission rate in dogs with lymphoma. Factors like age and disease stage influenced remission, while small size and absence of thrombocytopenia predicted longer remission duration.
Area of Science:
- Veterinary Oncology
- Canine Cancer Research
Background:
- Lymphoma is a common cancer in dogs.
- Combination chemotherapy offers a treatment option for canine lymphoma.
Purpose of the Study:
- To evaluate the efficacy of the VELCAP-L chemotherapy regimen in dogs with lymphoma.
- To identify pretreatment factors predicting remission and remission duration.
- To assess the toxicity profile of the VELCAP-L regimen.
Main Methods:
- Retrospective evaluation of 98 dogs with lymphoma treated with VELCAP-L.
- Analysis of pretreatment characteristics to identify predictors of response and remission duration.
- Assessment of treatment-related toxicities.
Main Results:
- A 69% complete remission rate was observed.
- Median remission duration was 55 weeks.
- Factors negatively impacting remission included advanced stage, constitutional signs, older age, and dyspnea.
- Factors positively impacting remission duration included smaller body size and absence of pretreatment thrombocytopenia.
- Toxicoses were common but rarely fatal, with no identified predictive factors.
Conclusions:
- VELCAP-L is an effective treatment for dogs with stage I-III lymphoma.
- Treatment is particularly beneficial for young, small dogs.
- Further research may explore optimizing VELCAP-L for specific canine patient populations.